Table 3.

All-grade and severe immune checkpoint inhibitor-mediated colitis (IMC) as predictors of progression-free survival (PFS) and overall survival (OS) in the entire GeRI cohort, using Cox proportional hazards models with 90-day landmark

IMC		PFS			OS
	HR	95% CI	p-value	HR	95% CI	p-value
All-grade	0.80	0.55–1.17	0.26	0.40	0.24–0.66	3 x 10-04
Severe	0.61	0.34–1.09	0.09	0.23	0.09–0.55	9 x 10-04

All p-values are two-sided.

Statistically significant results are highlighted in bold.

IMC immune checkpoint inhibitor-mediated colitis, PFS progression-free survival, OS overall survival, HR hazards ratio, CI confidence interval.

All models are adjusted for age at diagnosis, sex, histology, type of therapy, recruiting site, and 5 principal components.